Listen: A J.P. Morgan recap, a plan to bust pharma monopolies, and a website for cancer patients

Listen: A J.P. Morgan recap, a plan to bust pharma monopolies, and a website for cancer patients

The Readout LOUD Listen: A J.P. Morgan recap, a plan to bust pharma monopolies, and a website for cancer patients By Rebecca Robbins @rebeccadrobbins , Damian Garde @damiangarde , and Adam Feuerstein @adamfeuerstein January 16, 2020 W hy weren’t there any big deals announced this week? What does the word “equivalar” mean? And why is information about prognosis so hard to find? We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we recap what happened — and what didn’t — this week at the J.P. Morgan Healthcare Conference in San Francisco. Then, we talk about one of the biggest stories of the conference — the launch of a new company called EQRx aiming to develop cheaper medicines — with the health care veteran behind it, Alexis Borisy. Finally, we chat with Stephen Buck, the entrepreneur behind a new website called CancerSurvivalRates.com , which is designed to give cancer patients information about their odds of survival. For more on what we cover, here are all of the stories we wrote about J.P. Morgan ; here’s the news on EQRx ; and here’s more on CancerSurvivalRates.com . advertisement We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on Apple Podcasts , Stitcher , Google Play , or wherever you get your podcasts. And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email readoutloud@statnews.com .



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More